Clinical trials: Dermatitis
Atopic Dermatitis
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
- Trial name
- NCT00125333
- Testing
- NF-kappaB Decoy
- Where
- 9 sites in United States
- Volunteers
- 75 people
- Sponsor
- Anesiva, Inc.
Atopic Dermatitis
Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis
The purpose of this study is to compare the safety and efficacy profiles of Watson Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America LLC's Elidel® (pimecrolimus) Cream, 1%, and to…
- Trial name
- NCT02791308
- Testing
- Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
- Where
- 53 sites in United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Dermatitis Atopic
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live…
- Trial name
- HYDRO (NCT06015308)
- Testing
- Amlitelimab, Tdap vaccine, PPS vaccine
- Where
- 57 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- Sanofi
Atopic Dermatitis
Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis
Novel therapies for AD that avoid immunosuppression and potential carcinogensis are needed. EpiCeram™ , a topical cream, represents a novel class of therapy for skin disorders that does not contain corticosteroids or other…
- Trial name
- NCT00616538
- Testing
- Epiceram(r), Fluticasone Propionate 0.05%
- Volunteers
- 121 people
- Sponsor
- Ceragenix Pharmaceuticals
Atopic Dermatitis
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
- Trial name
- NCT06345404
- Testing
- Soquelitinib
- Where
- 16 sites in United States
- Volunteers
- 82 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Atopic Dermatitis
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Primary Objective: To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03912259
- Testing
- Dupilumab, Emollient (moisturizer)
- Where
- 27 sites in China
- Volunteers
- 165 people
- Sponsor
- Sanofi
Atopic Dermatitis
Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
The primary objective of the present multicentre, prospective, non-interventional study (NIS) is gathering knowledge on the actual use and effectiveness of Elidel® in Chinese patients with mild to moderate AD affecting sensitive…
- Trial name
- NCT04976868
- Testing
- Pimecrolimus 1% Top Cream
- Where
- 10 sites in China
- Volunteers
- 130 people
- Sponsor
- Mylan Inc.
Severe Atopic Dermatitis (AD)
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
This study is researching an approved drug called dupilumab (called "study drug"). Dupilumab is approved in the United States for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe…
- Trial name
- BUILD-PEDS (NCT07187089)
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis.
- Trial name
- NCT06383468
- Testing
- AK120
- Where
- 59 sites in China
- Volunteers
- 420 people
- Sponsor
- Akeso
Atopic Dermatitis
A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)
This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT01732510
- Testing
- MK-8226
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Dermatitis
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
- Trial name
- NCT01259323
- Testing
- REGN668
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects.
- Trial name
- NCT06614907
- Testing
- QL2108 injection, Dupixent®
- Where
- China
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Dermatitis, Atopic
A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Atopic dermatitis (AD) is among the most common chronic types of inflammatory skin disease and it is characterised by exacerbations or relapses over years.
- Trial name
- NCT03901144
- Testing
- 2% urea/20% glycerol cream, Miniderm® 20% cream, Diprobase® cream
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- ACO Hud Nordic AB
Chronic Hand Eczema
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema…
- Trial name
- NCT06004050
- Testing
- Delgocitinib, Vehicle cream
- Where
- 37 sites in China
- Volunteers
- 362 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Contact Dermatitis
A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB
This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.
- Trial name
- NCT04853823
- Testing
- PDC-APB
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hapten Sciences, Inc.
Atopic Dermatitis, Eczema, Atopic
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit [day (D) 0] and 4 follow-up visits (D30, D60, D90, and D120).
- Trial name
- NCT05575882
- Testing
- Skin hydration, Barrier function measurement, Potential of hydrogen measurement (pH)
- Where
- 3 sites in Argentina, India and 1 more
- Volunteers
- 100 people
- Sponsor
- NAOS Argentina S.A.
Dermatitis
A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.
- Trial name
- NCT03706040
- Testing
- Risankizumab
- Where
- 65 sites in United States, Australia and 3 more
- Volunteers
- 172 people
- Sponsor
- AbbVie
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
Long-term tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis and prevent…
- Trial name
- NCT00480610
- Testing
- tacrolimus ointment
- Where
- 22 sites in Austria, Belgium and 11 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Inc